Now that the ball has been dropped on Pacific Biosciences, and with the Genia lawsuit, what is the status quo on this business unit? What is happening with the Genia lawsuit? Otherwise too, Genia really only had a proof of concept and no real product prototype. The only product that I am aware of is the SeqCap target enrichment system. The ctDNA kits are probably a little late into the market since Guardant Health already has a huge market segment captured. Besides, every company into cancer diagnostics has developed or is actively developing their own version of the ctDNA assay. So, is the SeqCap system really enough to sustain the entire business unit? What are people being told by management at this point?
